L-asparaginase therapy in children with advanced leukemiaThe Southwest cancer chemotherapy study group

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

“…[2][3][4][5][6][7] Since that time, asparaginase has become an essential component of multiagent chemotherapy for childhood ALL. 3,4,[7][8][9][10][11][12][13][14][15][16] In the United States prior to November 2011, two asparaginase preparations received approval for use by the US Food and Drug Administration (FDA): native Escherichia coli asparaginase and pegaspargase.…”

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase

“…Asparaginase is a universally used component of childhood acute lymphoblastic leukemia (ALL) treatments, in both the remission induction phase and the postinduction period (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). The critical role of asparaginase in the context of multiagent chemotherapy has been amply demonstrated by clinical studies showing direct relations between treatment outcome and dose intensity of asparaginase (11) and between an inferior outcome and the use of an asparaginase preparation with a shorter half-life (12).…”

Asparagine Synthetase Chemotherapy

“…ASNase therefore likely exerts its effects indirectly by depleting asparagine in the blood, which is followed by an efflux of cytoplasmic asparagine from leukemic blasts (1). The use of Escherichia coli ASNase as a single agent leads to nearly complete remission in 40% to 60% of cases of ALL (10,11), and, in combination with vincristine and prednisone, increases the remission rate up to 95% in cases of childhood ALL. Unfortunately, three factors limit the clinical utility of ASNase in cancer therapy (8,12).…”